רווח למניה בשנים עשר החודשים האחרונים: PureTech Health PLC (PRTC)

PureTech Health plc (PRTC) operates as a biopharmaceutical incubator, monetizing assets through spin-offs supported by an elite team of M&A experts. The change in TTM net income per share confirms the effectiveness of the strategy, where the value -4.59 describes the current yield level. High brand authority in immunology and neurology makes this scientific hub a recognized leader in innovation.

For the biopharmaceutical holding company PureTech Health (PRTC), which invests in high-tech R&D projects, the rolling annual earnings per share reflects the actual efficiency of monetizing scientific innovations. This metric calculates net income distributed across the total share issuance, allowing investors to assess capital resilience against molecule discovery costs and the risk of margin compression.